-
Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-07
Abstract Background Pembrolizumab has been indicated in the treatment of solid tumors with high frequency microsatellite instability (MSI-H) or high tumor mutational burden (TMB-H); however, real-world data on the effectiveness of pembrolizumab with or without chemotherapy in this molecular subset remain limited. Our retrospective study evaluated the clinical efficacy and safety of pembrolizumab in
-
Clinical immunotherapy in pancreatic cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Xiaorong Ye, Yue Yu, Xiaohu Zheng, Hongdi Ma
-
Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Bingyu Li, Kaifeng Jin, Zhaopei Liu, Xiaohe Su, Ziyue Xu, Ge Liu, Jingtong Xu, Hailong Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Weijuan Zhang
-
Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Jiawei Yue, Hui Guo, Peng Xu, Jinhong Ma, Weifeng Shi, Yumin Wu
-
Riboflavin-LSD1 axis participates in the in vivo tumor-associated macrophage morphology in human colorectal liver metastases Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Cristiana Soldani, Giulia De Simone, Michela Anna Polidoro, Aurelia Morabito, Barbara Franceschini, Federico Simone Colombo, Achille Anselmo, Flavio Milana, Ana Lleo, Guido Torzilli, Roberta Pastorelli, Matteo Donadon, Laura Brunelli
-
Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Xinru Fan, Zijun Yan, Yunkai Lin, Qing Wang, Li Jiang, Xiaomeng Yao, Liwei Dong, Lei Chen, Tuan Zhao, Jieqiong Zhao, Heping Hu, Hui Wang
-
Molecular classification reveals the sensitivity of lung adenocarcinoma to radiotherapy and immunotherapy: multi-omics clustering based on similarity network fusion Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Jianguo Zhang, Yangyi Li, Weijing Dai, Fang Tang, Lanqing Wang, Zhiying Wang, Siqi Li, Qian Ji, Junhong Zhang, Zhengkai Liao, Jing Yu, Yu Xu, Jun Gong, Jing Hu, Jie Li, Xiuli Guo, Fajian He, Linzhi Han, Yan Gong, Wen Ouyang, Zhihao Wang, Conghua Xie
-
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Gerald S. Falchook, James Reeves, Sunil Gandhi, David R. Spigel, Edward Arrowsmith, Daniel J. George, Janet Karlix, Gayle Pouliot, Maureen M. Hattersley, Eric T. Gangl, Gareth D. James, Jeff Thompson, Deanna L. Russell, Bhavickumar Patel, Rakesh Kumar, Emerson Lim
-
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Tanguy Y. Seiwert, Sophie Wildsmith, Jérôme Fayette, Kevin Harrington, Maura Gillison, Myung-Ju Ahn, Shunji Takahashi, Jared Weiss, Jean-Pascal Machiels, Shrujal Baxi, Valerie Baker, Brent Evans, Nassim Morsli, Jill Walker, Katia Real, Anne L’Hernault, Amanda Psyrri
-
Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Zhengjie Dai, Xuan Lin, Xu Wang, Xuan Zou, Yu Yan, Ruijie Wang, Yusheng Chen, Yesiboli Tasiheng, Mingjian Ma, Xu Wang, He Cheng, Xianjun Yu, Chen Liu
-
Neutrophils seeking new neighbors: radiotherapy affects the cellular framework and the spatial organization in a murine breast cancer model Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 C. M. Reichardt, M. Muñoz-Becerra, A. Rius Rigau, M. Rückert, R. Fietkau, G. Schett, U. S. Gaipl, B. Frey, L. E. Muñoz
-
Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Wenjun Liu, Xitu Luo, Zilang Zhang, Yepeng Chen, Yongliang Dai, Jianzhong Deng, Chengyu Yang, Hao Liu
-
Oct4 activates IL-17A to orchestrate M2 macrophage polarization and cervical cancer metastasis Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Zhuoqiong Bian, Xiaoling Wu, Qing Chen, Qing Gao, Xiang Xue, Yidong Wang
-
Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Lujun Shen, Hongtong Tan, Juan Nie, Yiquan Jiang, Gulijiayina Nuerhashi, Han Qi, Fei Cao, Chunyong Wen, Shuanggang Chen, Tianqi Zhang, Wei Zheng, Peng Liu, Ying Liu, Tao Huang, Dandan Li, Xiaoshi Zhang, Weijun Fan
-
Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-24 Narendiran Rajasekaran, Xiaoguang Wang, Sruthi Ravindranathan, Daniel J Chin, Su-Yi Tseng, Scott L Klakamp, Kate Widmann, Varun N Kapoor, Vladimir Vexler, Patricia Keegan, Sheng Yao, Theresa LaVallee, Sanjay D Khare
-
Granzyme B+ B cells detected by single-cell sequencing are associated with prognosis in patients with intrahepatic cholangiocarcinoma following liver transplantation Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-22
Abstract B cells possess anti-tumor functions mediated by granzyme B, in addition to their role in antigen presentation and antibody production. However, the variations in granzyme B+ B cells between tumor and non-tumor tissues have been largely unexplored. Therefore, we integrated 25 samples from the Gene Expression Omnibus database and analyzed the tumor immune microenvironment. The findings uncovered
-
Multiplexed analysis of macrophage polarisation in pulmonary metastases of microsatellite stable colorectal cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-22 Topias Karjula, Hanna Elomaa, Sara A. Väyrynen, Teijo Kuopio, Maarit Ahtiainen, Olli Mustonen, Iiris Puro, Anne Niskakangas, Jukka-Pekka Mecklin, Jan Böhm, Erkki-Ville Wirta, Toni T. Seppälä, Eero Sihvo, Fredrik Yannopoulos, Olli Helminen, Juha P. Väyrynen
-
Targeting myeloperoxidase limits myeloid cell immunosuppression enhancing immune checkpoint therapy for pancreatic cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-17
Abstract Pancreatic ductal adenocarcinoma is a devastating disease characterized by an extreme resistance to current therapies, including immune checkpoint therapy. The limited success of immunotherapies can be attributed to a highly immunosuppressive pancreatic cancer microenvironment characterized by an extensive infiltration of immune suppressing myeloid cells. While there are several pathways through
-
Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-17 Wenxin Xu, Jialei Weng, Minghao Xu, Qiang Zhou, Shaoqing Liu, Zhiqiu Hu, Ning Ren, Chenhao Zhou, Yinghao Shen
-
Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-16 Hui-min Lian, Jia-liang Wu, Wei-jian Liufu, Tian-tian Yu, Shao-qing Niu, Yong Bao, Fang Peng
-
Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-15 Jin Peng, Guangfeng Luo, Yongchao Yu, Kang Ning, Xuekui Liu
-
Immunogenic cell death in colorectal cancer: a review of mechanisms and clinical utility Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-14
Abstract Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality worldwide. Despite several clinical advances the survival of patients with advanced colorectal cancer remains limited, demanding newer approaches. The immune system plays a central role in cancer development, propagation, and treatment response. Within the bowel, the colorectal mucosa is a key barrier and site
-
Low-intensity pulsed ultrasound activated the anti-tumor immunity by irradiating the spleen of mice in 4 T-1 breast cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Yi Xia, Meijie Yang, Xinfang Xiao, Wentao Tang, Juan Deng, Liu Wu, Haopeng Xu, Yilin Tang, Wenzhi Chen, Yan Wang
-
Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Anan Chen, Zhiwu Yu, Na Ma, Xinyu Lu, Yajing Zhang, Weikang Xu, Yiyue Wang, Jiayi Xie, Yuqi Qin, Guoheng Mo, Sha Wu, Jinlin Hou, Wei Zhu
-
Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Konstantinos Ntostoglou, Sofia D. P. Theodorou, Tanja Proctor, Ilias P. Nikas, Sinclair Awounvo, Athanasia Sepsa, Vassilis Georgoulias, Han Suk Ryu, Ioannis S. Pateras, Christos Kittas
-
Identification macrophage signatures in prostate cancer by single-cell sequencing and machine learning Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Zhen Kang, Yu-Xuan Zhao, Ren Shun Qian Qiu, Dong-Ning Chen, Qing-Shui Zheng, Xue-Yi Xue, Ning Xu, Yong Wei
-
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13
Abstract Combining immunotherapies with distinct mechanisms of action has the potential to overcome treatment resistance and improve outcomes. The inducible T-cell co-stimulator (ICOS) agonist feladilimab is directed at enhancing T-cell activation and function, thereby promoting an antitumor response. INDUCE-2 (NCT03693612) was a Phase I/II, open-label, two-part study evaluating the anti-ICOS agonist
-
Investigating the immunological function of alpha-2-glycoprotein 1, zinc-binding in regulating tumor response in the breast cancer microenvironment Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Toru Hanamura, Kozue Yokoyama, Shigehisa Kitano, Hiroshi Kagamu, Makiko Yamashita, Mayako Terao, Takuho Okamura, Nobue Kumaki, Katsuto Hozumi, Takayuki Iwamoto, Chikako Honda, Sasagu Kurozumi, Jennifer K. Richer, Naoki Niikura
-
Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Sweta Karan, Eunkyeong Jung, Christine Boone, Nicole F. Steinmetz
-
Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Kathryn Kline, Tim Luetkens, Rima Koka, Michael E. Kallen, Wengen Chen, Haroon Ahmad, Destiny Omili, Thierry Iraguha, Etse Gebru, Xiaoxuan Fan, Alexis Miller, Nishanthini Dishanthan, Jillian M. Baker, Kenneth A. Dietze, Kim G. Hankey, Jean A. Yared, Nancy M. Hardy, Aaron P. Rapoport, Saurabh Dahiya, Djordje Atanackovic
-
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13
Abstract The response rate of anti-PD1 therapy is limited, and the influence of anti-PD1 therapy on cancer patients is unclear. To address these challenges, we conducted a longitudinal analysis of plasma proteomic changes with anti-PD1 therapy in non-small cell lung cancer (NSCLC), alveolar soft part sarcoma (ASPS), and lymphoma patients. We included 339 plasma samples before and after anti-PD1 therapy
-
Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cells Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13
Abstract Breast cancer stands as a formidable global health challenge for women. While neoantigens exhibit efficacy in activating T cells specific to cancer and instigating anti-tumor immune responses, the accuracy of neoantigen prediction remains suboptimal. In this study, we identified neoantigens from the patient-derived breast cancer cells, PC-B-142CA and PC-B-148CA cells, utilizing whole-genome
-
Targeting metabolic sensing switch GPR84 on macrophages for cancer immunotherapy Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Jianying Li, Anjun Ma, Ruohan Zhang, Yao Chen, Chelsea Bolyard, Bao Zhao, Cankun Wang, Thera Pich, Wantong Li, Nuo Sun, Qin Ma, Haitao Wen, Steven K. Clinton, William E. Carson, Zihai Li, Gang Xin
-
Targeting monoamine oxidase A: a strategy for inhibiting tumor growth with both immune checkpoint inhibitors and immune modulators Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13
Abstract Monoamine oxidase A (MAOA) is a membrane-bound mitochondrial enzyme present in almost all vertebrate tissues that catalyzes the degradation of biogenic and dietary-derived monoamines. MAOA is known for regulating neurotransmitter metabolism and has been implicated in antitumor immune responses. In this review, we retrospect that MAOA inhibits the activities of various types of tumor-associated
-
Enhanced T cell immune activity mediated by Drp1 promotes the efficacy of PD-1 inhibitors in treating lung cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-10 Jietao Ma, Jun Song, Xiaofang Yi, Shuling Zhang, Li Sun, Letian Huang, Chengbo Han
-
Adipose-derived stem cell exosomes promote tumor characterization and immunosuppressive microenvironment in breast cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-31 Qin Zhu, Yukun Cao, Jiaqi Yuan, Yu Hu
-
Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-30
Abstract Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC). However, no head-to-head phase-3 randomized controlled trials (RCTs) have compared the efficacy of different ICI-based combination therapies. Here, we compared the efficacy of various first-line ICI-based combination therapies in patients with mRCC
-
A comprehensive pan-cancer analysis of prognostic value and potential clinical implications of FTH1 in cancer immunotherapy Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-28 Yuejun Luo, Chengming Liu, Yuxin Yao, Xiaoya Tang, Enzhi Yin, Zhiliang Lu, Nan Sun, Jie He
-
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27
Abstract The small, heavily glycosylated protein CD24 is primarily expressed by many immune cells and is highly expressed mostly in cancer cells. As one of the most crucial biomarkers of cancers, CD24 is frequently highly expressed in solid tumors, while tumor-associated macrophages express Siglec-10 at high levels, Siglec-10 and CD24 can interact on innate immune cells to lessen inflammatory responses
-
Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Mikel Gurrea-Rubio, Qi Wu, M. Asif Amin, Pei-Suen Tsou, Phillip L. Campbell, Camila I. Amarista, Yuzo Ikari, William D. Brodie, Megan N. Mattichak, Sei Muraoka, Peggy M. Randon, Matthew E. Lind, Jeffrey H. Ruth, Yang Mao-Draayer, Shengli Ding, Xiling Shen, Laura A. Cooney, Feng Lin, David A. Fox
-
A CAR-T response prediction model for r/r B-NHL patients based on a T cell subset nomogram Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Xiaomei Zhang, Rui Sun, Meng Zhang, Yifan Zhao, Xinping Cao, Ruiting Guo, Yi Zhang, Xingzhong Liu, Cuicui Lyu, Mingfeng Zhao
-
Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Debin Cheng, Zhao Zhang, Dong Liu, Zhenzhou Mi, Weidong Tao, Jun Fu, Hongbin Fan
-
CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Jianghua Wang, Xiaoting Li, Guanxi Xiao, Jayesh Desai, Sophia Frentzas, Zhongmin Maxwell Wang, Yu Xia, Baiyong Li
-
The complex role of IL-10 in malignant ascites: a review Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Yue Huang, Kangni Zou, Heng Jiang, Zhengyu Li
-
Unexpected chronic lymphocytic leukemia B cell activation by bisphosphonates Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Andrea N. Mazzarello, Elena Gugiatti, Vanessa Cossu, Nadia Bertola, Davide Bagnara, Sonia Carta, Silvia Ravera, Chiara Salvetti, Adalberto Ibatici, Fabio Ghiotto, Monica Colombo, Giovanna Cutrona, Cecilia Marini, Gianmario Sambuceti, Franco Fais, Silvia Bruno
-
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagozdzon, Pawel Wisniewski
-
Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27
Abstract Clinically, a considerable number of non-small cell lung cancer (NSCLC) patients are unable to receive or resist chemotherapy, and the efficacy of non-chemotherapy treatment strategies based on anti-angiogenic agents combined with immune checkpoint blockade is still unsatisfactory. Neoantigen vaccine, based on personalized tumor DNA mutations, could elicit tumor specific T cell infiltration
-
Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 J. M. Versluis, E. P. Hoefsmit, H. Shehwana, P. Dimitriadis, J. Sanders, A. Broeks, C. U. Blank
-
Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Amit Sharma, Xiubao Ren, Antonio Rosato, Dario Sangiolo, Zibing Wang, Sarah Tettamanti, Yi Zhang, Eva Rettinger, Kevin Aaron Fenix, Roberta Sommaggio, Elisa Cappuzzello, Ingo G. H. Schmidt-Wolf
On August 30, 2023, experts from Germany and abroad met to discuss the successes and challenges of cytokine-induced killer cell (CIK) therapy, that recently celebrated its 30th anniversary providing treatment for cancer. This first virtual conference was hosted by CIO Bonn, a certified Comprehensive Cancer Center (CCC) funded by German Cancer Aid (DKH). In addition to keynote speakers involved in CIK
-
Novel mechanism of drug resistance triggered by tumor-associated macrophages through Heat Shock Factor-1 activation Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Alina D. Nikotina, Snezhana A. Vladimirova, Nadezhda E. Kokoreva, Valeria A. Nevdakha, Vladimir F. Lazarev, Liubov S. Kuznetcova, Elena Y. Komarova, Roman V. Suezov, Sergei Efremov, Elizaveta Leonova, Viktor G. Kartsev, Nikolay D. Aksenov, Boris A. Margulis, Irina V. Guzhova
-
Presence of Epstein–Barr virus (EBV) antigens detected by sensitive methods has no influence on local immune environment in diffuse large B cell lymphoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 T. Mangiaterra, R. Alonso-Alonso, A. Rabinovich, M. De Dios Soler, L. Galluzzo, M. Soria, S. Colli, E. De Matteo, S. M. Rodriguez Pinilla, P. Chabay
-
Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Koji Otsuka, Junya Isobe, Yoshiyuki Asai, Tomohisa Nakano, Kouya Hattori, Tomotake Ariyoshi, Takeshi Yamashita, Kentaro Motegi, Akira Saito, Masahiro Kohmoto, Masahiro Hosonuma, Atsuo Kuramasu, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma
-
An analysis pipeline for understanding 6-thioguanine effects on a mouse tumour genome Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Patricio Yankilevich, Loulieta Nazerai, Shona Caroline Willis, Kjeld Schmiegelow, Daniela De Zio, Morten Nielsen
-
Characterization of T cell receptor repertoire in penile cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-27 Junying Zhang, Yapeng Wang, Yiqiang Huang, Xintao Tan, Jing Xu, Qian Yan, Jiao Tan, Yao Zhang, Jun Zhang, Qiang Ma, Hailin Zhu, Jin Ye, Zhaojing Zhu, Weihua Lan
-
Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-19 Feihua Chen, Mouchun Gong, Dengcheng Weng, Zhaoqing Jin, Guofeng Han, Ziqiang Yang, Junjun Han, Jianjiang Wang
-
Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3 Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-19 Thomas Eichholz, Florian Heubach, Anne-Marie Arendt, Christian Seitz, Ines B. Brecht, Martin Ebinger, Tim Flaadt, Daniela Süsskind, Lisa Richter, Isabel Hülsenbeck, Leonie Zerweck, Sophia Göricke, Frank Paulsen, Frank Dombrowski, Christian Flotho, Stefan Schönberger, Petra Ketteler, Johannes Schulte, Peter Lang
-
Coordination of anti-CTLA-4 with whole-brain radiation therapy decreases tumor burden during treatment in a novel syngeneic model of lung cancer brain metastasis Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-19 K. E. Blethen, C. P. Wolford, G. L. Pecar, T. A. Arsiwala, E. Adjeroh, L. P. Dykstra, B. N. Kielkowski, P. R. Lockman
-
Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-05 M Costa-Garcia, JJ Rojas, MD Ramos, P Barlabé, P Calvo, J Navas, R Alemany, R Moreno
-
CD204-positive M2-like tumor-associated macrophages increase migration of gastric cancer cells by upregulating miR-210 to reduce NTN4 expression Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-04 Chin-Wang Chen, Hao-Chen Wang, I-Min Tsai, I-Shu Chen, Chang-Jung Chen, Ya-Chin Hou, Yan-Shen Shan
-
PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-01-04 Nai-Wen Su, Shuen-Han Dai, Kate Hsu, Kuo-Ming Chang, Chun-Chuan Ko, Chen-Wei Kao, Yi-Fang Chang, Caleb G. Chen